
1.15 Delayed Data As of 3:59pm ET | ![]() Today’s Change | 0.97 Today|||52-Week Range 3.50 | -40.67% Year-to-Date |
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI) Nov 30 / Zacks.com - Paid Partner Content |
Previous close | 1.15 |
Today’s open | 1.17 |
Day’s range | 1.10 - 1.19 |
Volume | 72,725 |
Average volume (3 months) | 242,043 |
Market cap | $73.4M |
Earnings growth (last year) | +69.60% |
Earnings growth (this year) | +20.74% |
Earnings growth (next 5 years) | -- |
Revenue growth (last year) | -- |
P/E ratio | NM |
Price/Sales | -- |
Price/Book | 0.65 |
Next reporting date | March 20, 2024 |
EPS forecast (this quarter) | -$0.11 |
Annual revenue (last year) | $0.00 |
Annual profit (last year) | -$29.2M |
Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters New Haven, Connecticut |